Pseudomonas aeruginosa Infection in Cancer Patients

References

• Cross A, Allen J R, Burke J. Nosocomial infections due to Pseudomonas aeruginosa: review of recent trends. Rev Infect Dis 1983; 5: S837–S845, (Suppl 5)
   PubMedGoogle Scholar
• Favero M S, Carson L A, Bond W W, Petersen N J. Pseudomonas aeruginosa. Growth in distilled water from hospitals. Science 1971; 173: 836–837
   PubMed Web of Science ®Google Scholar
• Kominos S D, Copeland C E, Grosiak B, Postic B. Introduction of Pseudomonas aeruginosa into a hospital via vegetables. Appl Microbiol 1972; 24: 567–570
   PubMedGoogle Scholar
• Schimpff S C, Moody M, Young V M. Relationship of colonization with Pseudomonas aeruginosa to development of pseudomonas bacteremia in cancer patients. Antimicrob Agents Chemother: 1970; 240–244
   PubMedGoogle Scholar
• Bodey G P. Epidemiological studies of pseudomonas species in patients with leukemia. Am J Med Sci 1970; 260: 82–89
   PubMed Web of Science ®Google Scholar
• Whitecar JP, Jr., Luna M, Bodey G P. Pseudomonas bacteremia in patients with malignant diseases. Am J Med Sci 1970; 260: 216–223
   Web of Science ®Google Scholar
• Peterson P K. Host defense against Pseudomonas aeruginosa. Pseudomonas aeruginosa. International Symposium, LD Sabbath. Hans Huber Publisher, Bern 1980; 103–118
   Google Scholar
• Pollack M. Pseudomonas aeruginosa exotoxin A. N Engl J Med 1980; 302: 1360–1362
   PubMed Web of Science ®Google Scholar
• Iglewski B H, Rabat D. NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin. Proc Natl Acad Sci (USA) 1975; 72: 2284–2288
   PubMed Web of Science ®Google Scholar
• Atik M, Liu P V, Hanson B A, Amini S, Rosenberg C F. Pseudomonas endotoxin shock: a preliminary report of studies in dogs. J Am Med Assoc 1968; 205: 134–140
   PubMed Web of Science ®Google Scholar
• Pavlovskis O R, Callahan LT M, Pollack M. Pseudomonas aeruginosa exotoxin. Microbiology, D Schlessinger. American Society for Microbiology, Washington, DC 1976; 252–256
   Google Scholar
• Cross A S, Sadoff J C, Iglewski B H, Sokol P A. Evidence for role of toxin A in the pathogenesis of infection with Pseudomonas aeruginosa in humans. J Infect Dis 1980; 142: 535–546
   Google Scholar
• Pollack M, Young L S. Protective activity of antibodies to exotoxin A and lipopoly saccharide at the onset of Pseudomonas aeruginosa septicemia in man. J Clin Invest 1979; 63: 276–286
   PubMed Web of Science ®Google Scholar
• Liu P V. Toxins of Pseudomonas aeruginosa. Pseudomonas aeruginosa: Clinical Manifestations of Infection and Current Therapy, RG Dogget. Academic Press, New York 1979; 63–88
   Google Scholar
• Berka R M, Gray G L, Vasil M L. Studies of phospholipase (heat-labile hemolysin) in Pseudomonas aeruginosa. Infect Immun 1981; 34: 1071–1074
   PubMed Web of Science ®Google Scholar
• Tillotson J R, Lerner A M. Characteristics of non-bacteremic Pseudomonas pneumonia. Ann Intern Med 1968; 68: 295–307
   PubMed Web of Science ®Google Scholar
• Woods D E, Straus D C, Johanson WG, Jr., Bass J A. Role of pile in adherence of Pseudomonas aeruginosa to mammalian buccal epithelial cells. Infect Immun 1980; 29: 1146–1151
   PubMed Web of Science ®Google Scholar
• Ramphal R, Small P M, Shands JW, Jr. Adherence of Pseudomonas aeruginosa to trachael cells injured by influenza infection or by endobracheal intubation. Infect Immun 1980; 27: 614–619
   PubMed Web of Science ®Google Scholar
• Brown M RW, Foster J HS, Clamp J R. Composition of Pseudomonas aeruginosa slime. Biochem J 1969; 112: 521–526
   PubMed Web of Science ®Google Scholar
• Schwarzman S, Boring JR UJ. Antiphagocytic effect of slime from a mucoid strain of Pseudomonas aeruginosa. Infect Immun 1971; 3: 762–767
   PubMed Web of Science ®Google Scholar
• Sensakovic J W, Bartell P F. The slime of Pseudomonas aeruginosa: biological characterization and possible role in experimental infection. J Infect Dis 1974; 129: 101–109
   PubMed Web of Science ®Google Scholar
• Young L S, Armstrong D. Human immunity to Pseudomonas aeruginosa. In vitro interaction of bacteria, polymorphonuclear leucocyte and serum factors. J Infect Dis 1972; 126: 257–276
   PubMed Web of Science ®Google Scholar
• Reynolds M Y. Pulmonary host defenses in rabbits after immunization with pseudomonas antigens: the interaction of bacteria, antibodies, macrophages and lymphocytes. J Infect Dis 1974; 130: S134–S142, (Suppll)
   PubMed Web of Science ®Google Scholar
• Pollack M, Anderson SE, Jr. Toxicity of Pseudomonas aeruginosa exotoxin A for human macrophages. Infect Immun 1978; 19(1092)10–96
   Google Scholar
• Chester I R, Meadow P M, Pitt T L. The relationship between the 0-antigenic lipopolysaccharides and serological specificity in strains of Pseudomonas aeruginosa of different 0-serotypes. J Gen Microbiol 1973; 78: 305–318
   PubMedGoogle Scholar
• Peterson P K, Kim Y, Schmeling D, Lindemann M, Verhoef J, Onie P G. Complement mediated phagocytosis of Pseudomonas aeruginosa. J Lab Clin Med 1978; 99: 883–894
   Google Scholar
• Bjornson A B, Michael J G. Factors in human serum promoting phagocytosis of Pseudomonas aeruginosa. 1. Interaction of opsonins with the bacterium. J Infect Dis 1974; 130: 5119–5126, Suppl
   Google Scholar
• Southam C M, Pillemer L. Serum properdin levels and cancer cell homografts in man. Proc Soc Exp Biol Med 1957; 96: 596–601
   PubMed Web of Science ®Google Scholar
• Dorff G J, Geimer N F, Rosenthal D R. Pseudomonas septicemia: illustrated evolution of its skin lesions. Arch Intern Med 1971; 128: 591–595
   PubMed Web of Science ®Google Scholar
• Huminer D, Siegmen-Igra Y, Morduchowicz G, Pitlik S. Ecthyma gangrenosum without bacteremia: report of six cases and review of the literature. Arch Intern Med 1987; 147: 299–301
   PubMed Web of Science ®Google Scholar
• Kusne S, Eibling D E, Yu VL. Gangrenous cellulitis associated with gram-negative bacilli in pancytopenic patients. Dilemma with respect to effective therapy. Am J Med 1988; 85: 490–494
   PubMed Web of Science ®Google Scholar
• Fainstein V, Andres A, Umphrey J, Hopfer R L. Hair clipping: another hazard for granulocytopenic patients. J Infect Dis 1988; 158: 655–656
   PubMed Web of Science ®Google Scholar
• Rosenoff S H, Wolf M L, Ghabner B A. Pseudomonas blepharoconjunctivitis. A complication of combination chemotherapy. Arch Ophthalmol 1974; 91: 490–4491
   PubMed Web of Science ®Google Scholar
• Salit I E, Miller B, Wigmore W, Smith J A. Bacteria flora of the external canal in diabetics and non-diabetics. Laryngoscope 1982; 92: 672–673
   PubMed Web of Science ®Google Scholar
• Sobie S, Brodsky L, Stanievich J F. Necrotizing external otitis in children: a report of two cases and review of the literature. Laryngoscope 1987; 97: 598–601
   PubMed Web of Science ®Google Scholar
• Rubin J, Yu V L. Malignant external otitis: insights into pathogenesis, clincial manifestations, diagnosis and therapy. Am J Med 1988; 85: 391–398
   PubMed Web of Science ®Google Scholar
• Chandler J R. Malignant external otitis and facial paralysis. Otolaryngol Clin North Am 1979; 7: 375–383
   Google Scholar
• Caplan E S, Hoyt H J. Nosocomial sinusitis. J Am Med Assoc 1982; 247: 639–641
   Web of Science ®Google Scholar
• Wagner M L, Rosenberg M S, Fernbach D J, Singleton E B. Typhlitis: A complication of leukemia in childhood. Am J Roentgen, Radiol Ther Nucl Med 1970; 109: 341–350
   PubMed Web of Science ®Google Scholar
• Schimpf S C, Wiernik P M, Block J B. Rectal abscess in cancer patients. Lancet 1972; 2: 844–847
   PubMed Web of Science ®Google Scholar
• Rolston K., Paulino A, Elting L. Perirectal infections in cancer patients. Proc Intersci Conf Antimicrob Agents Chemother. New York 1987, Abstr #966
   Google Scholar
• Barnes S G, Sattler F R, Ballard J O. Perirectal infections in acute leukemia. Improved survival after incision and debridement. Ann Intern Med 1984; 100: 515–518
   PubMed Web of Science ®Google Scholar
• Tillotson J R, Lerner A M. Characteristics of nonbacteremic pseudomonas pneumonia. Ann Inter Med 1968; 68: 295–307
   PubMed Web of Science ®Google Scholar
• Bodey G P, Jadeja L, Elting L. Pseudomonas bacteremia: Retrospective analysis of 410 Episodes. Arch Inter Med 1985; 145: 1621–1629
   PubMed Web of Science ®Google Scholar
• Schimpff S C, Greene W M, Young V M, Wiernik P M. Significance of Pseudomonas aeruginosa in the patient with leukemia or lymphoma. J Infect Dis 1974; 130: 5524–5531, Suppl
   Google Scholar
• Fishman L S, Armstrong D. Pseudomonas aeruginosa bacteremia in patients with neoplastic disease. Cancer 1972; 30: 764–773
   PubMed Web of Science ®Google Scholar
• Tapper M L, Armstrong D. Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease. A progress report. J Infect Dis 1974; 130: 514–523, Suppl
   Google Scholar
• Bryant R E, Hood A F, Hood C E, Koenig M G. Factors affecting mortality of gram-negative rod bacteremia. Arch Intern Med 1971; 127: 120–128
   PubMed Web of Science ®Google Scholar
• Bisbe J, Gatell J M, Puig J. Pseudomonas aeruginosa bacteremia. Univariate and multivariate analysis of factors influencing the prognosis of 133 episodes. Rev Infect Dis 1988; 10: 629–635
   PubMedGoogle Scholar
• Andriole V T. Synergy of carbenicillin and gentamicin in experimental infections with pseudomonas. J Infect Dis 1971; 124: 546–555, Suppl
   Google Scholar
• Andriole V T. Antibiotic synergy in experimental infection with Pseudomonas II. The effect of carbenicillin, cephalothin, or cephanone combined with tobramycin or gentamicin. J Infect Dis 1974; 129: 124–133
   PubMed Web of Science ®Google Scholar
• Sculier J P, Klastersky J. Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. Am J Med 1984; 76: 429–435
   PubMed Web of Science ®Google Scholar
• Hector R E, Collins M S, Pennington J E. Treatment of experimental Pseudomonas aeruginosa pneumonia with a human IgM monoclonal antibody. J Infect Dis 1989; 160: 483–489
   PubMed Web of Science ®Google Scholar
• Collins H H, Gross A S, Dobet A. Oral ciprofloxacin on a monoclonal antibody to lipopolysaccharide protect leucopenic rats from lethal infection with Pseudomonas aeruginosa. J Infect Dis 1989; 159: 1073–1082
   PubMed Web of Science ®Google Scholar
• Applebaum F R, Bowles C A, Makuch R W, Deisseroth A B. Granulocyte transfusion therapy of experimental pseudomonas septicemia. Study of cell dose and collection technique. Blood 1978; 52: 323–331
   PubMed Web of Science ®Google Scholar
• Dale D C, Reynolds H Y, Pennington J E. Experimental pseudomonas pneumonia in leucopenic dogs: comparison of therapy with antibiotics and granulocyte transfusions. Blood 1976; 47: 869–876
   PubMed Web of Science ®Google Scholar
• Sordelli D O, Cerquetti M C, Fontan P A, Meiss R P. Piroxicam treatment protects mice from lethal pulmonary challenge with Pseudomonas aeruginosa. J Infect Dis 1989; 159: 232–238
   PubMed Web of Science ®Google Scholar
• Rolston K VI, Chandrasekar P H, LeFrock J L, Schell R F. The activity of cefazidime, other β-lactams, and aminoglycosides against Pseudomonas aeruginosa. Chemotherapy 1984; 30: 31–34
   PubMed Web of Science ®Google Scholar
• Chandrasekar P M, Schell R F, LeFrock J L. Activity of cefsulodin, other β-lactams, and aminoglycosides against Pseudomonas aeruginosa. Chemotherapy 1984; 30: 165–169
   PubMed Web of Science ®Google Scholar
• Hoy J F, Rolston K VI, Ho D H: In vitro activity of BRL 36650, a new semisynthetic penicillin. Antimicrob Agents Chemother 1986; 29: 972–976
   PubMed Web of Science ®Google Scholar
• Bodey G P, Bolivar R, Fainstein V, Jadeja L. Infections caused by Pseudomonas aeruginosa. Rev Infect Dis 1983; 5: 279–313
   PubMedGoogle Scholar
• Jackson G G, Riff L J. Pseudomonas bacteremia: pharmacologic and other basis for failure of treatment with gentamicin. J Infect Dis 1974; 124: 5185–5191, Suppl
   Google Scholar
• Bodey G P, Middleman E, Umsawadi T, Rodriguez V. Infections in cancer patients. Results with gentamicin sulfate therapy. Cancer 1972; 29: 1697–1701
   PubMed Web of Science ®Google Scholar
• Bodey G P. Aminoglycoside use in the compromised host. The Aminoglycosides, A Whelton, HC Neu. Marcel Dekker, New York 1982; 557–583
   Google Scholar
• Berk S L, Alvarez S, Ortega G. Clinical and microbiologic consequences of amikacin use during a 42-month period. Arch Intern Med 1986; 146: 538–541
   PubMed Web of Science ®Google Scholar
• Rolston K, Alvarez M E, Hoy J F. Comparative in vitro activity of cefpirome and other antimicrobial agents against isolates from cancer patients. Chemotherapy 1986; 32: 349–351
   Google Scholar
• Fuchs P C, Barry A L, Jones R N. In vitro activity and disc susceptibility of Timentin: current status. Am J Med 1985; 75: 25–32, Suppl 5B
   Google Scholar
• Jones R N, Barry A L, Packer R R. In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentations of the cefoperazone-sulbactam. J Clin Microbiol 1987; 25: 1725–1729
   PubMed Web of Science ®Google Scholar
• Bodey G P, Whitecar JP, Jr., Middleman E, Rodriguez V. Carbenicillin therapy for pseudomonas infections. J Am Med Assoc 1971; 218: 62–66
   PubMed Web of Science ®Google Scholar
• Bodey G P, Rodriguez V. The role of antipseudomonal penicillins in the management of infections in cancer patients. Ticarcillin (BRL 2288). International Symposium. Excerpta Medica, Amsterdam 1977; 151–157
   Google Scholar
• Bodey G P, Bolivar R, Fainstein V, Jadeja L. Infections caused by Pseudomonas aeruginosa. Rev Infect Dis 1983; 5: 279–313
   PubMedGoogle Scholar
• The E OR, TC International Antimicrobial Cooperative Therapy Group. Ceftazidine combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987; 317: 1692–1698
   PubMed Web of Science ®Google Scholar
• Bodey G P, Rodriguez V, Chang H Y, Narboni G. Fever and infection in leukemia patients. Cancer 1978; 41: 1610–1622
   PubMed Web of Science ®Google Scholar
• Anaissie E J, Fainstein V, Bodey G P. Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients. Am J Med 1988; 84: 581–589
   PubMed Web of Science ®Google Scholar
• Fainstein V, Bodey G P, Elting L. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. J Antimicrob Chemother 1983; 12: 101–110, Suppl A
   PubMed Web of Science ®Google Scholar
• Fainstein V, Eltin L, Pidik S. Ticarcillin plug clavulanic acid in the treatment of patients with cancer. Am J Med 1985; 79: 62–66, Suppl 5B
   PubMed Web of Science ®Google Scholar
• Bodey G P, FainsteinElting V. L. β-lactam regimens for the febrile neutropenic patient. Cancer 1990; 65: 9–16
   PubMed Web of Science ®Google Scholar
• Jones P G, Rolston K VI, Fainstein V. Aztreonam therapy in neutropenic patients with cancer. Am J Med 1986; 81: 243–248
   PubMed Web of Science ®Google Scholar
• Bodey G P, Alvarez M, Jones P G. Imipenem-cilastatin as initial therapy for febrile cancer patients. Antimicrob Agents Chemother 1986; 30: 211–214
   PubMed Web of Science ®Google Scholar
• Bodey G P, Rolston K, Jones P. Imipenem/cilastatin as secondary therapy for infections in cancer patients. J Antimicrob Chemother 1986; 18: 161–166, Suppl E
   PubMed Web of Science ®Google Scholar
• Rolston K VI, Ho D H, LeBlanc B, Bodey G P: In vitro evaluation of difloxacin (A-56619), A-56620, and other 4-quinolones against isolates from cancer patients. Chemotherapy 1987; 33: 419–427
   PubMed Web of Science ®Google Scholar
• Rolston K VI, Ho D H, LeBlanc B, Bodey G P. Comparative in vitro activity of the new difluoro-quinolone temafloxacin (A-62254) against bacterial isolates from cancer patients. Eur J Clin Microbiol Infect Dis 1988; 7: 684–686
   PubMed Web of Science ®Google Scholar
• Rolston K, Ho D H, LeBlanc B, Bodey G P: In vitro activity of fleroxacin (Ro 23–6240), a new fluorinated 4-quinolone against isolates from cancer patients. Chemotherapy 1988; 34: 448–454
   PubMed Web of Science ®Google Scholar
• Rolston K VI, LeBlanc B, Gooch G: In vitro activity of PD 117558, a new quinolone against bacterial isolates from cancer patients. J Antimicrob Chemother 1989; 23: 363–371
   PubMed Web of Science ®Google Scholar
• Rolston K VI, Ho D H, LeBlanc R, Bodey G P: In vitro evaluation of S-25930 and S-25932, two new quinolones, against aerobic gram-negative isolates from cancer patients. Antimicrob Agents Chemother 1987; 31: 102–103
   PubMed Web of Science ®Google Scholar
• King A, Phillips I. The comparative in vitro activity of peflox-acin. J Antimicrob Chemother 1986; 17: l–10, (Suppl B)
   Google Scholar
• Karp J E, Merz W G, Hendricksen C. Oral norfloxacin for prevention of gram-negative infections in patients with acute leukemia and granulocytopenia. Ann Intern Med 1987; 106: 1–7
   PubMed Web of Science ®Google Scholar
• Dekker A W, Rosenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukemia. A comparison of ciprofloxacin with trimethoprim/sulfamethoxazole and colistin. Ann Inter Med 1987; 106: 7–12
   PubMed Web of Science ®Google Scholar
• Haron E, Rolston K VI, Cunningham C. Oral ciprofloxacin for infections in cancer patients. J Antimicrob Chemother 1989; 24: 955–962
   PubMed Web of Science ®Google Scholar
• Rolston K VI, Haron E, Cunningham C, Bodey G P. Intravenous ciprofloxacin for infections in cancer patients. Am J Med 1989; 87: 2615–2655, Suppl 5A
   Google Scholar
• Bodey G P, Ho D H, Elting L. Survey of antibiotic susceptibility among gram-negative bacilli at a cancer center. Am J Med 1988; 85: 49–51, Suppl 1A
   PubMed Web of Science ®Google Scholar
• Parry M F, Panzer K B, Yukna M E. Quinolone resistance. Am J Med 1989; 87: 12S–16S, Suppl 5A
   PubMed Web of Science ®Google Scholar
• Klastersky J, Meunier-Carpentier F, Prevost J M. Significance of antimicrobial synergism for the outcome of gram-negative sepsis. Am J Med Sci 1977; 273: 157–167
   PubMed Web of Science ®Google Scholar
• Anderson E T, Young L S, Hewitt W L. Antimicrobial synergism in the therapy of gram-negative rod bacteremia. Chemotherapy 1978; 24: 45–54
   PubMed Web of Science ®Google Scholar
• Piccart M, Klastersky J, Muenier F. Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia. Antimicrob Agents Chemother 1984; 26: 870–875
   PubMed Web of Science ®Google Scholar
• Pizzo P A, Hathorn J W, Hiemenz J. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552–558
   PubMed Web of Science ®Google Scholar
• Parry M F, Neu M C, Merlino M. Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin. J Pediatr 1977; 90: 144–148
   PubMed Web of Science ®Google Scholar
• Fainstein V, Bodey G P, Bolivar R. Moxalactam plus ticarcillin or tobramycin for treatment of febrile episodes in neutropenic cancer patients. Arch Inter Med 1984; 144: 1776–1780
   Google Scholar
• Winston D J, Barrier R, Ho W G. Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients. Am J Med 1984; 77: 442–450
   PubMed Web of Science ®Google Scholar
• Rotstein C, Cimino M, Winkey K. Cefoperazone plus piper-cillin versus mezlocillin plus tobramycin as empiric therapy for febrile episodes in neutropenic patients. Am J Med 1989; 85: 36–39, Suppl lA
   Web of Science ®Google Scholar
• Benezra D, Kiehn T E, Gold J WM. Prospective study of infections in indwelling central venous catheters using quantitative blood cultures. Am J Med 1988; 85: 495–498
   PubMed Web of Science ®Google Scholar
• Young L S. The role of granulocyte transfusions in treating and preventing infection. Cancer Treat Rep 1983; 67: 109–111
   PubMedGoogle Scholar
• Young L S, Meyer R D, Armstrong D. Pseudomonas aeruginosa vaccine in cancer patients. Ann Intern Med 1973; 79: 518–527
   PubMedGoogle Scholar
• Haghbin M D, Armstrong D, Murphy M L. Controlled prospective trial of Pseudomonas aeruginosa vaccine in children with acute leukemia. Cancer 1973; 32: 761–766
   PubMedGoogle Scholar
• Pennington J E, Reynolds H Y, Wood R E. Use of a Pseudomonas aeruginosa vaccine in patients with acute leukemia and cystic fibrosis. Am J Med 1975; 58: 629–637
   PubMed Web of Science ®Google Scholar
• StoU BJ, Pollack M, Young L S. Functionally active monoclonal antibody that recognizes an epitope on the 0 side chain of Pseudomonas aeruginosa immunotype-1 lipopolysaccharide. Infect Immun 1986; 53: 656–662
   PubMed Web of Science ®Google Scholar
• Harkonen S, Scannon P, Mischak R P. Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and non-bacteremic patients. Antimicrob Agents Chemother 1988; 32: 710–716
   PubMed Web of Science ®Google Scholar
• Young L S, Gascon R, Alam S, Bermudez L EM. Monoclonal antibodies for treatment of gram-negative infections. Rev Infect Dis 1989; 11: S1564–S1571, Suppl7
   PubMedGoogle Scholar
• Pizzo P A. Considerations for the prevention of infectious com-lications in patients with cancer. Rev Infec Dis 1989; 11: S1551–1563, (Suppl 7)
   PubMedGoogle Scholar